Is TB-500 Legal in Florida? How to Access It Legally
HealthRX.com
Florida law does not settle TB-500 access
See the public record for TB-500
At a glance
- FDA approval / none; no approved product in Canada, Australia, the UK, the European countries FDA reviewed, or by the European Medicines Agency [1]
- Compounding lists / on neither list; the category 1 no-action policy does not cover it [2][3][7]
- Advisory committee / voted in favour on 23 July 2026; advice only, not binding [8][4]
- HHS draft policy / filed 28 October 2026; names TB-500 acetate injection; not an approval [4][5]
- Human data / no study giving TB-500 to a person [1]
- Florida / Chapter 465 of the Florida Statutes covers pharmacy licensure and permits [6]
What TB-500 is and where it stands
TB-500 is a synthetic, N-acetylated 7-amino-acid fragment of thymosin beta-4 (residues 17 to 23), not the 43-amino-acid protein itself [1]. It sits in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks (content dated 22 April 2026), which holds substances previously in category 2 whose nominators withdrew them; removal from category 2 was not a finding that it is safe [9]. FDA's stated concerns stay on record: no identified human exposure data, missing safety information, and immunogenicity risk from aggregation and peptide-related impurities in injectable peptides [9].
The July 2026 vote and the October 2026 draft
FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 on 23 July 2026 and voted in favour of adding it to the bulks list, against FDA staff's recommendation; the vote is advice only, and adding it takes formal rulemaking [8][4].
A draft HHS enforcement-discretion policy filed on 28 October 2026 (Federal Register document 2026-22192, publication scheduled 30 October 2026, comments due two weeks later) names TB-500 among six peptides [4][5]. It covers TB-500 acetate given subcutaneously or intramuscularly and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it where conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label 'This is a compounded drug product. Not for resale.' [4][5]. The notice says the draft does not establish rights for any person, is not binding on HHS or the public, and may be revisited if a safety signal or product quality issue arises; compounded drugs are not FDA-approved [4].
What Florida adds
Chapter 465 of the Florida Statutes sets out pharmacy licensure, permits and general requirements, including a nonresident sterile compounding permit [6]. The chapter's contents list does not mention TB-500.
What is known about safety in humans
FDA's July 2026 review found no article in which TB-500 was given to a human, and none of the three papers the nominator cited involved it in humans; there is no approved dose and no human dosing study [1]. FDA's adverse-event database search through 26 March 2025 retrieved no TB-500 reports, and its food and supplement complaint system retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment [1]. A single case in FDA's BPC-157 review describes a 40-year-old woman who developed widespread skin hyperpigmentation and gum darkening within a week of using a research-purpose BPC-157 plus TB-500 (5 mg/5 mg) product subcutaneously twice daily, recurring when she retried it; because the product held two peptides, FDA could not tell whether either caused it [10].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is TB-500 legal in Florida?
Did FDA approve TB-500 after the July 2026 vote?
Is TB-500 the same as thymosin beta-4?
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Chapter 465 - 2023 Florida Statutes - The Florida Senate.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.